Comparative Pharmacology
Head-to-head clinical analysis: ENHERTU versus TIBSOVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENHERTU versus TIBSOVO.
ENHERTU vs TIBSOVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate (ADC). The antibody is a humanized anti-HER2 IgG1, and the small molecule DXd is a topoisomerase I inhibitor. Upon binding to HER2 on tumor cells, the ADC undergoes internalization and intracellular cleavage, releasing DXd which causes DNA damage and apoptotic cell death.
Isocitrate dehydrogenase-2 (IDH2) inhibitor; targets mutant IDH2 isoforms to reduce 2-hydroxyglutarate (2-HG) levels, promoting myeloid differentiation.
5.4 mg/kg intravenously every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
500 mg orally once daily taken with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 5.5 days (range 4.5–7.5 days) for the antibody-drug conjugate, supporting every-3-week dosing.
Terminal elimination half-life: 50-60 hours, supporting once-daily dosing with steady-state reached in approximately 2 weeks.
Primarily biliary/fecal excretion (approximately 95% as unchanged drug); renal excretion is negligible (<1%).
Primarily hepatic metabolism (CYP3A4) and fecal excretion (77% unchanged and metabolites); renal elimination accounts for <1% of absorbed dose.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent